sporanox oral solution
j-c health care ltd - itraconazole - solution - itraconazole 10 mg/ml - itraconazole - itraconazole - sporanox oral solution is indicated for the treatment of oropharyngeal and esophageal candidiasis. prevention of fungal infection during neutropenia of immunodeficient patients.
sporal 100mg capsules
janssen-cilag international nv turnhoutsewes 30, b-2340 beerse, belgium - itraconazole - hard capsule - itraconazole 100 mg - antimycotics for systemic use
sporanox 10 mg/ml oral solution
janssen sciences ireland uc - itraconazole - oral solution - 10 milligram(s)/millilitre - triazole derivatives; itraconazole
sporanox 100mg capsules
janssen sciences ireland uc - itraconazole - capsule, hard - 100 milligram(s) - triazole derivatives; itraconazole
sporanox itraconazole 10 mg/ml oral liquid bottle
janssen-cilag pty ltd - itraconazole, quantity: 10 mg/ml - oral liquid, solution - excipient ingredients: propylene glycol; hydroxypropylbetadex; saccharin sodium; purified water; caramel; sorbitol solution (70 per cent) (non-crystallising); sodium hydroxide; hydrochloric acid; flavour - sporanox oral solution is indicated for: * the treatment of oral and/or oesophageal candidiasis in hiv-positive or other immunocompromised patients. * prophylaxis of fungal infections in neutropenic patients.
sporanox i.v. 10 mg/ml concentrate and solvent for solution for infusion
janssen sciences ireland uc - itraconazole - concentrate and solvent for solution for infusion - 10 milligram(s)/millilitre - triazole derivatives; itraconazole
itraconazole 10mg/ml oral solution
athlone pharmaceuticals limited - itraconazole - oral solution - triazole derivatives; itraconazole
ketoconazole 200mg tablets
hra pharma uk ltd - ketoconazole - tablet - 200mg
xtandi
astellas pharma europe b.v. - enzalutamide - prostatic neoplasms - endocrine therapy - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5.1).the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5.1).the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5.1).the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.
xtandi enzalutamide 40 mg soft capsule blister pack
astellas pharma australia pty ltd - enzalutamide, quantity: 40 mg - capsule, soft - excipient ingredients: gelatin; purified water; caprylocaproyl macrogolglycerides; butylated hydroxyanisole; butylated hydroxytoluene; titanium dioxide; sorbitol; glycerol; propylene glycol; ethyl acetate; ethanol; isopropyl alcohol; strong ammonia solution; iron oxide black; macrogol 400; polyvinyl acetate phthalate - xtandi is indicated for:,? the treatment of patients with metastatic hormone-sensitive prostate cancer.,? the treatment of patients with non-metastatic castration-resistant prostate cancer (see prosper, section 5.1 clinical trials).,? the treatment of patients with metastatic castration resistant prostate cancer following failure of androgen deprivation therapy in whom chemotherapy is not yet indicated.,? the treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel.